LUNGevity Awards for Translational Research
LUNGevity supports research in three tracks: career development, early detection, and targeted therapeutics.
Letters of intent for the 2017 Career Development Award program are no longer being accepted.
Career Development Awards
- 3-year grants, totaling $300,000
- Limit of one award per institution
Letter of Intent Deadline:
FEBRUARY 20, 2017
Career Development Awards
LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.
Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.
Projects that will be funded in 2017 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.
Early Detection and Interception Award
LUNGevity Foundation is collaborating with Stand up to Cancer and the American Lung Association (via LUNG FORCE) on a new initiative, the SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team. The Thomas G. Labrecque Foundation is also investing in this collaboration. Delving into the newly emerging field of lung cancer interception, the team is embarking on a 4-year research project to investigate early molecular or other changes that lead to cancer development. Early detection and interception are key elements for determining effective treatment options for patients and preventing the spread of cancer to other parts of the body, ultimately resulting in increased survival.
SU2C, with support from its Scientific Partner, the American Association for Cancer Research, has issued a Call for Ideas, seeking interdisciplinary and multi-institution teams of researchers to offer innovative approaches to cancer interception for lung cancer with the greatest promise for patient benefits faster. LUNGevity Foundation and the American Lung Association LUNG FORCE initiative will participate with SU2C in the evaluation and SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team selection. Go to the AACR page at https://proposalcentral.altum.com for program details.
LUNGevity’s Therapeutics Awards for Translational Research support research projects directed at individualized treatments, including targeted therapeutics and immunotherapy, that will make a difference in the clinical treatment and survival of patients. We are evaluating the structure of our Therapeutics Awards Program for maximum impact. Information on our next Therapeutics Award RFA will be posted at a later date.